Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

European Innovation Council · Finished

ReTreatPD Revolutionary therapeutic treatment for stopping progression of Parkinson's disease

Coordinator
Herantis Pharma Oyj, Finland
Runs
1 May 2023 to 30 April 2025
Status
Finished
EU funding
€2.5m
Total cost
€4.1m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190132320

What the project is doing

In the project's own words, from its summary on CORDIS.

Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, whereof 1.2 million in the EU. This chronic disabling disease affects the central nervous system, causing severe motor and non-motor symptoms. The high disease burden for patients and their family also comes with a big price tag for society, which is expected to increase dramatically with an ageing population. In EU the annual cost is 14 B€ currently.

The causes of PD are unknown and there is a broad spectrum of pathologies that ultimately lead to the loss of dopamine producing neurons in the brain. The current dopamine substitution treatments alleviate some of the symptoms, however, there is no cure for PD nor any disease-modifying therapies. Herantis has developed a new pharmaceutical HER-096 with the ability to affect PD pathology and potential to revolutionise the treatment of PD, thus alleviating the huge burden it now causes patients and healthcare.

Topics

Who is involved

OrganisationCityCountryRole
Herantis Pharma OyjEspooFinlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI